ImmunityBio ANKTIVA Offers $313.8K Savings per Responder and $151.4K per Cystectomy
IBRX•ImmunityBio’s economic model shows ANKTIVA plus BCG yields up to $313,775 lower cost per responder and $151,438 savings per avoided cystectomy over three years versus J&J’s TAR-200 in U.S. Medicare patients. This stems from higher modeled response rates (49.6% vs 45.9%) and reduced drug acquisition and administration costs.
1. Health economic analysis overview
ImmunityBio built a cost-consequence model using data from its QUILT-3.032 study and data from TAR-200’s SunRISe-1 trial to evaluate ANKTIVA plus BCG in U.S. Medicare patients with BCG-unresponsive non-muscle-invasive bladder cancer over a three-year horizon.
2. Cost savings and response rates
The analysis estimated that ANKTIVA plus BCG lowers cost per complete responder by $313,775 and achieves savings of $151,438 per avoided cystectomy compared with TAR-200, driven by a modeled complete response rate of 49.6% versus 45.9%.
3. Drivers of economic advantage
Projected savings are attributed to reduced drug acquisition and administration expenses combined with higher modeled response rates, which delay or prevent radical cystectomy and lower overall healthcare expenditures.
4. Competitive and payer implications
Although based on an indirect comparison rather than a head-to-head study, these results reinforce ANKTIVA’s value proposition in the NMIBC market and could shape future Medicare reimbursement and payer coverage decisions.
